Lv1
100 积分 2024-09-01 加入
A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2‐ breast cancer‐FINEST study
1个月前
已完结
Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study
6个月前
已完结
Spatial distributions of CD8 and Ki67 cells in the tumor microenvironment independently predict breast cancer-specific survival in patients with ER+HER2– and triple-negative breast carcinoma
6个月前
已完结
MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor-positive HER2-negative breast cancer
6个月前
已完结
Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer
6个月前
已完结
Combination of autophagy inhibitors with high-dose CDK4/6 inhibitors offers new hope for advanced HR+/HER2− breast cancer
6个月前
已关闭
Computational Optimization and In Silico Analysis for the Discovery of New HER2 and CDK4/6 Drug Candidates for Breast Cancer
6个月前
已完结
Unveiling the Future of Breast Cancer Therapy: Cutting-Edge Antibody-Drug Conjugate Strategies and Clinical Outcomes
6个月前
已完结
Management of hormone receptor-positive, HER2-negative early breast cancer
6个月前
已完结
Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis
6个月前
已完结
皖公网安备34019202002308
